Acuvi (ACUVI) Q3 2026 earnings summary

Executive summary

• Q3 revenue was SEK 47.4m vs SEK 57.8m YoY; reported EBITDA was -SEK 0.3m and adjusted EBITDA was SEK 6.4m.

• 9M free cash flow reached SEK 10.2m vs -SEK 27.5m in 9M 2025; management prioritizes top-line growth and cash flow.

Financial highlights

• Q3 gross profit was SEK 20.1m vs SEK 28.5m; reported gross margin was 42% vs 49% YoY.

• Q3 reported EBITDA was -SEK 0.3m vs SEK 6.7m; EBIT was -SEK 7.1m vs SEK 1.2m, with EBIT margin at -15% vs 2%.

• Q3 net loss was SEK 8.2m vs SEK 2.6m; EPS was -SEK 0.25 vs -SEK 0.08.

• 9M revenue was SEK 148.7m vs SEK 150.6m; EBITDA was -SEK 1.3m vs SEK 26.4m and EBIT was -SEK 23.9m vs SEK 13.0m.

• 9M net loss was SEK 27.5m vs net income of SEK 5.1m; EPS was -SEK 0.83 vs SEK 0.16.

Outlook and guidance

• Management expects PiezoMotor and Asian sales to offset much of the lost TPA Motion distribution business through the rest of 2026; PiezoMotor is expected to achieve or exceed 50% full-year growth.

• Sales resources may be added at PiezoMotor and Sensapex, balancing growth initiatives with cost control; this may reduce earlier expectations for SEK 10m net cost savings.

• Management expects positive cash flow to improve quarter by quarter, but gave no timing for sustainable positive cash flow excluding inventory effects.

• IVF-instrument prototypes are progressing, with revenue possible as early as 2027.